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Enzyme replacement therapy (ERT) for FD 
was introduced in 2001. Two isoforms of human 
α ‑galactosidase are presently available: agalsidase 
alfa and agalsidase beta, both administered in‑
travenously every other week. This therapy has 
been approved in most European and Asian coun‑
tries, Australia and Canada, while in the United 
States, only agalsidase beta has been approved by 
the Food and Drug Administration.4 It has been 
documented that the ERT use in pediatric patients 
can significantly clear GL ‑3 deposits, ameliorate 
early symptoms of the disease, and improve the 
quality of life.4 This hopefully may prevent fur‑
ther disease progression and overt organ damage. 
The efficacy of ERT has been also demonstrated in 
clinical trials in adult FD patients, by stabilizing 
or slowing progression of severe organ damage, 
or even improvement of the function of affect‑
ed organs.1 It is still unknown, however, whether 
ERT might extend life expectancy in this disease.
Unfortunately, FD patients in Poland have no 
access to reimbursed ERT within our health care 
system, even if such treatment is recommended 
by European expert groups, at least in selected 
patients.5 Poland is the only country in the Euro‑
pean Union that does not reimburse ERT in FD. 
Moreover, in Poland there are no specialized cen‑
ters, which could provide comprehensive care for 
these individuals. Access to the diagnostic proce‑
dures is also very limited, particularly for adult 
patients, while molecular testing, according to 
our knowledge, is not available within the pub‑
lic health care service. In the last few years, a se‑
lected group of Polish patients (about 20) are con‑
tinuing ERT as part of the so called “charity pro‑
gram” supported by pharmaceutical companies, 
after these patients had completed their partic‑
ipation in clinical trials. The remaining patients 
do not receive ERT, often despite severe and dis‑
abling symptoms, due to very high costs of such 
treatment (about 800 000 PLN per year). 
At University Hospital in Krakow, the ERT is 
currently provided at the expense of pharmaceu‑
tical companies for 7 patients (4 men, 3 women). 
In these patients, we have observed a considerable 
stabilization of the clinical course, including renal 
and heart function, as well as a reduction in pain 
and gastrointestinal symptoms, resulting in a sig‑
nificant improvement in the quality of life. More‑
over, in 3 patients, we have documented resump‑
tion of sweat production. However, the charity 
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Fabry disease (FD) is an ultrarare, devastating, 
and progressive X ‑linked inherited metabolic dis‑
order, caused by a deficiency of the lysosomal en‑
zyme α ‑galactosidase A.1 Its pathogenesis is related 
to the lysosomal accumulation of globotriaosylce‑
ramide (GL ‑3) and other glycosphingolipids, lead‑
ing to cellular and microvasculature dysfunction 
and subsequent organ damage.1 The prevalence of 
FD is estimated at about 1:100 000 in the general 
population.1 According to the latest annual report 
of the Polish Association for Families Affected by 
Fabry (in Polish, Stowarzyszenie Rodzin z Chorobą 
Fabry’ego), there are currently 73 confirmed cases 
in Poland,2 indicating that the disease is underdi‑
agnosed. The phenotypes of the disease can range 
from severe multiorgan manifestations, commonly 
found in men, to apparently asymptomatic cours‑
es observed in some women. However, progressive 
organ damage develops in both sexes. Particularly 
renal failure and severe cardiovascular events re‑
sult in a shortened life ‑expectancy.1
The first clinical symptoms usually develop 
in childhood. The diagnosis, however, is often 
delayed and properly established in adulthood. 
Therefore, internists should be aware of the typ‑
ical symptoms of FD. The most characteristic ear‑
ly manifestations are episodes of burning pain in 
the distal extremities, accompanied by chronic 
paresthesias. Gastrointestinal symptoms are also 
common, like abdominal pain (often postpran‑
dial), diarrhea, nausea, vomiting, and anorexia. 
Other classic manifestations include skin lesions 
in the form of angiokeratomas and decreased abil‑
ity to sweat with exercise, cold, and heat intoler‑
ance. The disease may also cause corneal lesions 
(cornea verticillata) or tinnitus and hearing loss.3 
Confirmation of the disease in hemizygous males 
is based on the marked α ‑galactosidase A deficien‑
cy measured in leukocytes, plasma, or serum.1 In 
heterozygous females, however, enzyme analy‑
sis is usually inconclusive due to random chro‑
mosome X inactivation. Therefore, in these sub‑
jects molecular testing (genotyping) is required.1 
On the other hand, the diagnosis of FD can be 
challenging in those with confirmed genetic mu‑
tation and absence of the characteristic FD fea‑
tures. Such situation might be observed in fami‑
ly members of some affected patients.1
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program does not provide continuous access to 
the ERT. Recently, in our 56 ‑year ‑old male patient, 
a 6 ‑month treatment interruption was associat‑
ed with a non–ST ‑segment elevation myocardi‑
al infarction, followed by an ischemic stroke re‑
lated to the percutaneous coronary intervention.
Meanwhile, it is generally believed that only 
early medical intervention might improve long‑
‑term prognosis. Later, when irreversible organ 
damage occurs, it will likely be ineffective.1 This 
finding imposes a significant psychological burden 
on our FD patients. Unfortunately, it seems that 
systemic solutions for diagnosis and treatment 
of rare diseases in Poland have come to a stand‑
still in the last several years.
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